← Back to Clinical Trials
Recruiting NCT01050504

NCT01050504 Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT01050504
Status Recruiting
Phase
Sponsor University of Washington
Condition Localized Renal Pelvis and Ureter Urothelial Carcinoma
Study Type OBSERVATIONAL
Enrollment 1,500 participants
Start Date 2009-08
Primary Completion 2029-01-31

Trial Parameters

Condition Localized Renal Pelvis and Ureter Urothelial Carcinoma
Sponsor University of Washington
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,500
Sex MALE
Min Age 18 Years
Max Age N/A
Start Date 2009-08
Completion 2029-01-31
Interventions
Cytology Specimen Collection ProcedureLaboratory Biomarker Analysis

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study collects and studies tissue and blood samples from patients with prostate or bladder/urothelial cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other parts of the body. Studying samples of blood and tissue samples from patients with prostate or bladder/urothelial cancer in the laboratory may help doctors learn more about new biomarkers, potential drug targets, and resistance developing in response to treatment. It may also help doctors find better ways to treat the cancer.

Eligibility Criteria

Inclusion Criteria: * Patients with localized and/or metastatic bladder/urothelial or prostate cancer who have disease in the primary organ, biopsy accessible bone metastases (collaborating radiologists will determine if bone metastasis is appropriate for biopsy) or soft tissue metastases are eligible; men and women without cancer are eligible to have blood or normal tissue collected if acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder); in patients without malignancy, no additional tissue beyond that necessary for care will be procured * Ability to adequately understand and give informed consent * Local or metastatic disease to soft tissue or bone at sites accessible to biopsy with minimal risk of complications Or the ability to obtain tissue with minimal risk of complication from a surgical procedure being conducted as a part of another research study Or for standard of care purposes or patients who have archival tissue collected for

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology